Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease

• DOI: 10.1164/rccm.201206-1113oc
• Publication Date: 2012-09-15T10:43:33Z
• Authors: Mette Thomsen; Morten Dahl; Peter Lange; Jørgen Vestbo; Børge G. Nordestg...
• Keywords: Male; Risk; Chronic Obstructive; Lung Neoplasms; Vital Capacity; Myocardial Infarction; Myocardial Ischemia; comorbidities; chronic obstructive pulmonary disease; Comorbidities; Pulmonary Disease; Leukocyte Count; Pulmonary Disease, Chronic Obstructive; 03 medical and health sciences; 0302 clinical medicine; Forced Expiratory Volume; Diabetes Mellitus; Humans; Aged; Inflammation; Heart Failure; Chronic obstructive pulmonary disease; biomarkers; Fibrinogen; Pneumonia; Middle Aged; 3. Good health; C-Reactive Protein; Diabetes Mellitus, Type 2; inflammation; Biological Markers; Female; Inflammation Mediators; Type 2; Biomarkers

Rationale: Patients with chronic obstructive pulmonary disease (COPD) have evidence of systemic inflammation that may be implicated in the development comorbidities.Objectives: To test hypothesis elevated levels three inflammatory biomarkers are associated increased risk comorbidities COPD.Methods: We examined 8,656 patients COPD from two large Danish population studies and during a median 5 years' follow-up recorded hospital admissions due to major as endpoints.Measurements Main Results: measured baseline C-reactive protein (CRP), fibrinogen, leukocyte count, ischemic heart disease, myocardial infarction, failure, type II diabetes, lung cancer, pneumonia, embolism, hip fracture, depression for all participants. Multifactorially adjusted was by factor 2.19 (95% confidence interval, 1.48–3.23) individuals (CRP > 3 mg/L, fibrinogen 14 μmol/L, count 9 × 109/L) versus at or below these limits. Corresponding hazard ratios were 2.32 (1.34–4.04) 2.63 (1.71–4.04) 3.54 (2.03–6.19) 4.00 (2.12–7.54) 2.71 (2.03–3.63) pneumonia. There no consistent differences function biomarkers.Conclusions: Simultaneously CRP, two- fourfold COPD. These an additional tool clinicians conduct stratified management